Annual report pursuant to Section 13 and 15(d)

Acquisitions - Narrative (Details)

v3.22.2.2
Acquisitions - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Apr. 06, 2021
Apr. 02, 2021
Oct. 20, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2022
Payments to Acquire Businesses, Net of Cash Acquired, Total       $ 225,352    
Gain (Loss) on Escrow Settlement         $ 7,169  
Changzhou Eminence Biotechnology [Member]            
Business Acquisition, Percentage of Voting Interests Acquired     47.60%      
Business Combination, Consideration Transferred, Total       18,750    
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value     $ 9,000      
Payments to Acquire Businesses, Gross   $ 6,000        
Business Combination, Step Acquisition, Equity Interest in Acquiree, including Subsequent Acquisition, Percentage, Total   57.40%        
Variable Interest Entity, Primary Beneficiary, Maximum Loss Exposure, Portion Stemming from Initial Investment           $ 15,800
Payments to Acquire Businesses, Net of Cash Acquired, Total     $ 9,800 9,765    
Acquisition of Asuragen, Inc. [Member]            
Business Combination, Consideration Transferred, Total       233,887    
Adjustments to deferred taxes and goodwill       4,400    
Payments to Acquire Businesses, Net of Cash Acquired, Total $ 216,000     $ 215,587    
Acquisition of Asuragen, Inc. [Member] | Developed Technology Rights [Member]            
Finite-Lived Intangible Asset, Useful Life (Year) 14 years   13 years      
Acquisition of Asuragen, Inc. [Member] | Customer Relationships [Member]            
Finite-Lived Intangible Asset, Useful Life (Year) 16 years   10 years      
Acquisition of Asuragen, Inc. [Member] | Trade Names [Member]            
Finite-Lived Intangible Asset, Useful Life (Year) 5 years          
Acquisition of Asuragen, Inc. [Member] | Noncompete Agreements [Member]            
Finite-Lived Intangible Asset, Useful Life (Year) 3 years